These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38334012)

  • 21. Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients.
    Vischer AS; Kuster GM; Twerenbold R; Pfister O; Zhou Q; Villiger A; Poglitsch M; Krähenbühl S; Mayr M; Osswald S; Haschke M; Burkard T
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the inhibitory effects of telmisartan on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
    Konta M; Nagakawa M; Sakatani A; Akabane R; Miyagawa Y; Takemura N
    J Vet Cardiol; 2018 Oct; 20(5):376-383. PubMed ID: 30126722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The renin-angiotensin-aldosterone system and its suppression.
    Ames MK; Atkins CE; Pitt B
    J Vet Intern Med; 2019 Mar; 33(2):363-382. PubMed ID: 30806496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
    Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.
    Lantis AC; Ames MK; Werre S; Atkins CE
    J Vet Pharmacol Ther; 2015 Oct; 38(5):513-7. PubMed ID: 25771846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers.
    Siragy HM
    J Hypertens; 2010 Jan; 28(1):2-8. PubMed ID: 19797978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
    da Silva PM
    Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
    Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm.
    Konda T; Enomoto A; Aritomi S; Niinuma K; Koganei H; Ogawa T; Nitta K
    Am J Nephrol; 2009; 30(2):155-61. PubMed ID: 19325231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized placebo-controlled clinical trial of a chewable formulation of amlodipine for the treatment of hypertension in client-owned cats.
    Huhtinen M; Derré G; Renoldi HJ; Rinkinen M; Adler K; Aspegrén J; Zemirline C; Elliott J
    J Vet Intern Med; 2015; 29(3):786-93. PubMed ID: 25857394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.
    Loader J; Taylor FC; Lampa E; Sundström J
    J Am Heart Assoc; 2022 Jun; 11(11):e025289. PubMed ID: 35624081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative effects of losartan and amlodipine on activities of sympathetic nerve, renin-angiotensin-aldosterone system and brain natriuretic peptide in the elderly hypertensive patients].
    Tsutamoto T; Maeda K; Mabuchi N; Tsutsui T; Ohnishi M; Kinoshita M
    Nihon Ronen Igakkai Zasshi; 2002 May; 39(3):303-7. PubMed ID: 12073593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
    Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
    Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.
    Ames MK; Atkins CE; Lantis AC; zum Brunnen J
    J Renin Angiotensin Aldosterone Syst; 2016; 17(1):1470320316633897. PubMed ID: 27009288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone.
    Brown JM; Williams JS; Luther JM; Garg R; Garza AE; Pojoga LH; Ruan DT; Williams GH; Adler GK; Vaidya A
    Hypertension; 2014 Feb; 63(2):273-80. PubMed ID: 24191286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The past, present and future of renin-angiotensin aldosterone system inhibition.
    Mentz RJ; Bakris GL; Waeber B; McMurray JJ; Gheorghiade M; Ruilope LM; Maggioni AP; Swedberg K; Piña IL; Fiuzat M; O'Connor CM; Zannad F; Pitt B
    Int J Cardiol; 2013 Sep; 167(5):1677-87. PubMed ID: 23121914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
    Ferrario CM
    Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
    Mentz RJ; Stevens SR; DeVore AD; Lala A; Vader JM; AbouEzzeddine OF; Khazanie P; Redfield MM; Stevenson LW; O'Connor CM; Goldsmith SR; Bart BA; Anstrom KJ; Hernandez AF; Braunwald E; Felker GM
    JACC Heart Fail; 2015 Feb; 3(2):97-107. PubMed ID: 25543972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging drugs which target the renin-angiotensin-aldosterone system.
    Steckelings UM; Paulis L; Unger T; Bader M
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):619-30. PubMed ID: 21905943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.